Treatment of Plaque Psoriasis

Introduction to Treatment Approaches

The American Academy of Dermatology recommends a stepwise approach for the treatment of plaque psoriasis, with topical corticosteroids as first-line therapy for mild to moderate disease and biologics for moderate to severe disease 1, 2

The American Academy of Dermatology recommends class 1-3 (high to ultra-high potency) topical corticosteroids for up to 4 weeks for plaque psoriasis not involving intertriginous areas 1, 2
Efficacy rates for ultra-high potency corticosteroids range from 58% to 92% in randomized controlled trials 1
The American Academy of Dermatology recommends dosing of 1-2 times daily, with appropriate potency selection based on disease location, disease severity, and patient age 1, 2

The American Academy of Dermatology recommends biologics as first-line treatment for moderate to severe plaque psoriasis due to their efficacy and acceptable safety profiles 3
TNF-α inhibitors (etanercept, adalimumab, infliximab) are effective for both skin and joint manifestations 3
The recommended starting dose for infliximab is 5 mg/kg administered at weeks 0, 2, and 6, then every 8 weeks thereafter 3

The American Academy of Dermatology recommends topical corticosteroids (classes 1-7) for at least 4 weeks for scalp psoriasis 1, 2
Calcipotriene foam and calcipotriene plus betamethasone dipropionate gel are effective for 4-12 weeks for scalp psoriasis 2, 4
Lower potency corticosteroids are recommended to minimize adverse effects for facial and intertriginous psoriasis 2
Tacrolimus 0.1% can be used for up to 8 weeks for facial psoriasis 5
Infliximab is recommended for moderate-to-severe nail psoriasis 3

The American Academy of Dermatology warns of the risk of skin atrophy, striae, and hypothalamic-pituitary-adrenal axis suppression with prolonged use of topical corticosteroids 2
Tachyphylaxis (decreased effectiveness over time) may occur with topical corticosteroids 2
The American Academy of Dermatology recommends avoiding simultaneous use of vitamin D analogues with salicylic acid as the acidic pH inactivates calcipotriene 2, 4
If used with phototherapy, apply vitamin D analogues after treatment as UVA radiation can decrease concentration on skin 6, 4

For mild disease, start with high-potency topical corticosteroid once or twice daily for 2-4 weeks, then add or switch to vitamin D analogue for maintenance (up to 52 weeks) 1, 2, 4
For moderate disease, consider adding low-dose systemic therapy or phototherapy (narrowband UVB) 3
For severe disease, first-line treatment is biologics (TNF-α, IL-17, IL-23 inhibitors), with alternative options including traditional systemic agents (methotrexate, acitretin, cyclosporine) 3

For adults with mild‑to‑moderate plaque psoriasis, apply calcipotriene ointment 0.005 % twice daily (morning and evening) to affected areas for up to 52 weeks 7.

Scalp psoriasis: Use calcipotriene foam or a calcipotriene + betamethasone dipropionate gel for 4–12 weeks 7.
Facial psoriasis: Combine calcipotriene with hydrocortisone for 8 weeks; this regimen is more effective than calcipotriene alone on facial skin 7.
Body psoriasis: Apply calcipotriene ointment 0.005 % twice daily as monotherapy 7.

Adding a high‑potency topical corticosteroid (betamethasone dipropionate) to calcipotriene provides superior efficacy compared with either agent alone 7.
Schedule calcipotriene application in the evening and the high‑potency corticosteroid in the morning for optimal results 7.
An alternative maintenance schedule uses vitamin D analogues twice daily on weekdays and high‑potency corticosteroids twice daily on weekends 7.
When used together with biologic agents such as adalimumab or etanercept, adding calcipotriene/betamethasone further augments therapeutic efficacy 8.

Do not prescribe calcipotriene concurrently with salicylic acid, as the acidic pH inactivates calcipotriene and reduces its effectiveness 7.
If phototherapy is part of the treatment plan, instruct patients to apply calcipotriene after phototherapy sessions; pre‑treatment application diminishes calcipotriene concentration and thick layers can block UVB 7.

In patients receiving calcipotriene + betamethasone dipropionate, 69–74 % achieve clear or almost clear skin over a 52‑week period, with no serious adverse events such as striae or hypothalamic‑pituitary‑adrenal axis suppression 7.